| Autor: |
Marcelo Villaça, Lima, Marcelo Eidi, Ochiai, Juliano Novaes, Cardoso, Paulo César, Morgado, Robinson Tadeu, Munhoz, Antonio Carlos Pereira, Barretto |
| Rok vydání: |
2007 |
| Předmět: |
|
| Zdroj: |
Arquivos brasileiros de cardiologia. 91(3) |
| ISSN: |
1678-4170 |
| Popis: |
The incidence of hyperkalemia related to spironolactone use is low in stable heart failure; however, it has not been studied during decompensation.To evaluate the influence of spironolactone on serum potassium in decompensated heart failure (HF).In a cohort study, patients that had been hospitalized due to decompensated HF, with left ventricular ejection fraction (LVEF)0.45 and serum potassium between 3.5 and 5.5 mEq/l were selected. The patients were divided according to spironolactone use (Group S) or no use (Group C). The outcome was potassium increase (6.0 mEq/l) and the use of calcium polystyrene. A multivariate analysis through logistic regression was carried out and values of p0.05 were considered significant.A total of 186 patients (group S: 56; group C: 130) were studied; LVEF of 0.25, aged 55.5 years and 65.2% of them males. The incidence of hyperkalemia was 10.7% in group S and 5.4% in group C (p = 0.862). The multivariate analysis showed that serum urea60.5 mg/dl during the hospitalization presents a relative risk of 9.6 (95%CI 8.03 - 11.20; p = 0.005) for the occurrence of hyperkalemia.The incidence of hyperkalemia was two-fold higher with spironolactone use, but it was not statistically significant. The increase in urea levels was associated to the hyperkalemia. Randomized studies are necessary to clarify this issue. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
